The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Merck’s stock fell 1.77% to $80.93 while the market gained, despite rising 5.26% over the past month. The company’s upcoming ...

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its ...

Merck (MRK) ended the recent trading session at $80.93, demonstrating a -1.77% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.83%. At the same time, ...

The stock's fall snapped a four-day winning streak.

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. TaxStatus is the only firm to provide the comprehensive information advisors need to ...

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...